Dragon Sail Pharma is a monoculture industrialization platform wholly owned by Guilin Sanjin with a total investment of ￥690 million. It has built a best-in-class monoclonal antibody drugs production factory in Shanghai Lingang Industrial Area for clinical samples and commercial productions. The total scale of the platform is 6*2000L, and will be one of the largest single-anti-production bases in Shanghai.

Dragon Sail provides complete CDMO services across process development, GMP-compliant productions, quality research and IND/BLA applications. With its advanced production process and experienced team, DragonSail can help its partners shorten the time to market, improve the production effective, reduce the cost of drugs and improve the accessibility of patients to biological drugs.